April 13, 2015
Cambridge, MA — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today that it will present a series of posters at the 2015 American Association of Cancer Research (AACR) Annual Meeting being held April 18–22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA.
Title: Mutations in SF3B1 lead to aberrant splicing through cryptic 3' splice site selection and impair hematopoietic cell differentiation
Date and time: Monday, Apr 20, 2015, 1:00–5:00 p.m.
Title: Targeting MCL1-dependent cancers through RNA splicing modulation
Date and time: Tuesday, April 21, 2015, 8:00–12:00 p.m.
Title: Total synthesis of 6-deoxypladienolide D and assessment of splicing inhibitory activity in a mutant SF3B1 cancer cell line
Date and time: Wednesday, April 22, 2015, 8:00–12:00 p.m.
“The data to be presented at AACR highlights the excellent progress H3’s scientists have made over an incredibly short time frame in identifying a lead oncology drug candidate and validating our splicing modulation platform,” said Markus Warmuth, M.D., President and CEO of H3 Biomedicine. “The data in these presentations support our growing discovery program and provide insight into the identification of potential future drug candidates for a host of different cancers.”
“I believe that the progress made by the H3 scientific team is truly impressive and their achievements strengthen our support and commitment to continue to advance this unique scientific model to fulfill our mission to quickly deliver effective targeted cancer treatments to patients in need,” stated Haruo Naito, President and CEO of Eisai Co., Ltd.
About H3 Biomedicine Inc.
H3 Biomedicine is a privately held biopharmaceutical company focused on the discovery and early development of novel, targeted anti-cancer compounds for the unmet needs of genetically defined patient populations. H3 has leveraged its integrated expertise in genomics, tumor biology, bioinformatics and innovative synthetic organic chemistry to create an integrated drug development ecosystem to deliver patient-based, genomics-driven, small molecule drugs. In less than three years, H3 has developed four discovery platforms, which have produced two drug candidates for which the company expects to file investigational new drug (IND) applications in late 2015. Founded by a $200 million dollar investment from Eisai Inc., and given operational and strategic independence, H3 has delivered on Eisai’s confidence with multiple platforms generating multiple lead programs. Having reached this inflection point, H3 is considering additional collaborators to fully realize the potential of its growing pipeline of lead programs and drug candidates. H3 Biomedicine is based in Cambridge, Massachusetts. Visit h3biomedicine.com for more information.